MedNous

Single product model makes a comeback

Friday 5 February 2010

Country: Austria

As those who attend medical conferences know well, biotech executives like to talk about what they do in terms of models.

“The one-product model is dead, you have to have a platform,” one conference attendee will say while his colleague will reply, “My model is to both provide research services and to develop a proprietary drug pipeline.”

Implicit in the talk of dual strategies is the idea that it is no longer possible to simply patent the results of a single piece of research, find business angels to back it and develop the product to the proof-of-concept stage where it then becomes eligible for out-licensing. Yet, this very straightforward model can still be made to work.

A case in point is a deal announced on 3 February 2010 by the Austria